Advances in Rheumatology

Table 5 Correlation of IMT with demographic, clinical and laboratory characteristics

From: Methotrexate use, not interleukin 33, is associated with lower carotid intima-media thickness in patients with rheumatoid arthritis

Variable		IMT (mm - median (IQR))	P-value
Postmenopausal	No	0.60 (0.55–0.65)	0.001^a
	Yes	0.71 (0.6–0.8)
Extra-articular involvement	No	0.65 (0.58–0.76)	0.014^a
	Yes	0.72 (0.63–0.88)
SAH	Absent	0.60 (0.55–0.71)	0.001^a
	Present	0.72 (0.63–0.81)
Using antihypertensives	No	0.62 (0.56–0.71)	0.001^a
	Yes	0.73 (0.63–0.81)
Diabetes mellitus	Absent	0.65 (0.58–0.76)	0.003^a
	Present	0.84 (0.63–0.95)
Using hypoglycemic agents/insulin	No	0.65 (0.58–0.76)	0.001^a
	Yes	0.84 (0.7–1.02)
LDL within goal	No	0.7 (0.6–0.8)	0.012^a
	Yes	0.6 (0.6–0.7)
Metabolic syndrome	Absent	0.64 (0.58–0.74)	0.037^a
	Present	0.71 (0.6–0.84)
Using methotrexate	No	0.75 (0.62–0.87)	0.005^a
	Yes	0.63 (0.58–0.73)
CVR classification^c	High	0.73 (0.61–0.84)	< 0.001^b
	Intermediate	0.71 (0.64–0.77)
	Low	0.6 (0.54–0.64)
IL-33 positive^d	No	0.69 (0.59–0.85)	0.449^a
	Yes	0.66 (0.59–0.78)

^aMann-Whitney test; ^bKruskal-Wallis test
IMT intima-media thickness, IQR interquartile range, SAH systemic arterial hypertension; and CVR cardiovascular risk
^caccording to the Global Risk Score (Framingham)
^dIL-33 positive: serum IL-33 ≥ 23.4 pg/mL

Back to article page

ISSN: 2523-3106

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com